background 9

The Antibody Discovery Specialists.

We are antibody enthusiasts discovering biologics for our partners against the most challenging classes of reagent and therapeutic targets, royalty-free!


Learn about our platform

Twist announcement banner3



Twist announcement banner mobile

100+ Successful mAb Discovery Campaigns Targeting Cell Surface receptors.

Industry-leading solutions for therapeutic and reagent antibody developers. We have built a strong reputation on our ability to deliver outstanding science. We have custom-built gene-to-antibody solutions to support development efforts for:
  • Therapeutic antibodies against difficult targets such as GPCR, ion channels, glycan targets
  • Cell therapies
  • Point-of-care diagnostics
  • Reagent & anti-idiotypic antibodies supporting clinical trials
  • Anywhere else antibodies are needed
  • Fee-for-service, royalty-free partnership model 


Expertise in Antibody Discovery

Industry leading platform for challenging targets 
and royalty free!


GPCR-1Cell surface-1High homology-2

Anti-id-1cross reactive-2Functional antibodies



End-to-End Antibody Discovery Technologies


Therapeutic Discovery_workflow_2022-04-28


The Reviews Are In.

Pharma and biotech of various sizes and pipelines rely on Abveris.

Our platform rapidly generates and validates new targets for treating challenging cancers. Working with Abveris will enable us to quickly identify and select highly specific antibodies for those targets, so that we can take the best antibody forward to address the needs of particular patient populations.
Jeff Goldberg, CEO
Immunitas Therapeutics
At Promega, we struggled to acquire a high-affinity, high-specificity antibody against one target of interest. After failing with two previous vendors, we enlisted the help of Abveris and their DiversimAb approach, and we soon had a multitude of high-quality clones to choose from. We eventually chose a clone that far exceeded our expectations for performance. We were continually impressed by their high-quality analytical data, excellent communication, and overall collaborative spirit.

Speak with Abveris scientists about how to tackle challenges in antibody discovery.

Attend an Upcoming Webinar 
Watch Now 

Abveris News